Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Olverembatinib

The Chinese drug developer put a rocket booster under its share price after enlisting a Japanese rival as a new equity partner and unveiling plans for a U.S. listing.

Ascentage Pharma soars on deal with cancer drug competitor

The Chinese drug developer put a rocket booster under its share price after enlisting a Japanese rival as a new equity partner and unveiling plans for a U.S. listing Key…
June 27, 2024
6855.HK

FAST NEWS: Ascentage’s manufacturing center gets EU stamp of approval

The latest: Ascentage Pharma Group International (6855.HK) announced on Tuesday it recently received a zero-deficiency report following a Good Manufacturing Practice (GMP) compliance audit of its global manufacturing center by…
April 25, 2023
6855.HK

Recent Articles

The Chinese drug developer put a rocket booster under its share price after enlisting a Japanese rival as a new equity partner and unveiling plans for a U.S. listing.
June 27, 2024

Ascentage Pharma soars on deal with cancer drug competitor

6855.HK
April 25, 2023

FAST NEWS: Ascentage’s manufacturing center gets EU stamp of approval

6855.HK

RELATED ARTICLES

  1. December 24, 2024
    BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
    6855.HK
  2. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  3. December 12, 2024
    Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
  4. January 24, 2025
    BRIEF: Ascentage Pharma prices U.S. IPO at 20% discount, to raise up to $130 million
    6855.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Premium Content
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2024 Bamboo Works. All rights reserved.